{"filings":[{"id":2741917,"accession_number":"0001628280-26-060904","cik":2131524,"company_name":"Braveheart Bio, Inc.","ticker":"BRVE","form_type":"8-K","filed_at":"2026-09-08T20:06:55+00:00","items":["2.02","9.01"],"status":"ready","headline":"Braveheart Bio Q2 2026 net loss $18.6M; cash $527.3M after IPO; Phase 3 trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $122.8M at 6/30/26; $527.3M pro forma after Aug IPO net ~$404.5M; runway into 2029.","Net loss $15.0M; attributed to common stockholders $18.6M ($2.51/sh) vs $0.4M ($0.14/sh) in Q2 2025.","LIONHEART-HCM Phase 3 for oHCM initiated; first patient dosing expected 2026, interim results 2H 2027.","NOBLEHEART-HCM Phase 3 in nHCM expected to start 1H 2027 after Q2 Phase 2 data presented at HFA-ESC 2026.","R&D expense $11.1M (vs $0.0M), G&A $4.8M (vs <$0.1M) on advancement and public-company prep."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2133316,"accession_number":"0001628280-26-054842","cik":2131524,"company_name":"Braveheart Bio, Inc.","ticker":"BRVE","form_type":"8-K","filed_at":"2026-08-07T20:14:14+00:00","items":["5.03","9.01"],"status":"ready","headline":"Braveheart Bio files amended charter and bylaws post-IPO, authorizing 500M common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second amended and restated certificate of incorporation filed with Delaware on Aug 7, 2026, effective immediately prior to IPO completion.","Authorizes 500,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock.","Eliminates prior preferred stock series and removes stockholder ability to act by written consent or call special meetings.","Amended and restated bylaws establish advance notice procedures for stockholder proposals and board nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}